qingdao sigma chemical tirzepatide | China | Manufacturer Tirzepatide (LY3298176)|CAS 2023788-19-2|DC Chemicals

by Summer Kessel, RD, CSOWM, LDN Spring 2025 If youre using a GLP-1 medication for obesity treatment, youve probably noticed changes in your appetite, digestion and even how you think about food

GLP-1 therapies with Semaglutide, BHRT, and more for lasting results.

Strengths Acts via multiple pathways (GLP-1, AMPK, microbiome) Has existing human data showing reductions in fasting glucose, HbA1c, lipids Support receptor expression and islet health Limitations Low absorption and bioavailability Gastrointestinal discomfort is common (diarrhea, cramping)

AHA 2023 Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) sat down with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the SELECT trial

Existing literature is limited and has largely focused on postprandial hypoglycaemia as a surrogate for late dumping syndrome